Ophthalmology
2023 ACTIVITY INDICATORS
- 3 public competitive projects led: ISCIII
- 3 private projects led
- 19 clinical led trials
- 23 publications
- IF: 56.71
- Q1 publications: 5 (22%)
- 3 awards
- National public agency evaluators: 3 PI
- Members of editorial committees: 4 researchers
- 1 patent family with priority European application (EP22382119.0) and PCT/EP2023/053668
- 1 consensus document and 2 clinical guidelines
- 2 actions with an impact on society: conferences
- 4 visitors hosted and 4 months stay:
- University Hospital of Helsinky. Finland
- Medical University of Lublin. Poland
- University Hospital Center Sestre Milosrdnice. Croatia
- Ankara University Medical School. Turkey
Milestones
- First place in the ranking of the MRS MERCO 2023 health reputation monitor for the best Ophthalmology Service.
- Start-up of the Artificial Intelligence project for corneal transplants. PI22/01252_Validation of tomographic image biomarkers as predictors of the need for keratoplasty after cataract surgery in Fuchs' corneal dystrophy: multicentre study and artificial intelligence-assisted diagnosis. Funded by the ISCIII and led by Dr Arnalich.
- Development and publication of clinical practice guidelines published by the Spanish Society of Ophthalmology for the follow-up of glaucoma and the management of advanced glaucoma.
- 3D corneal construct patent: European priority application and PCT extension (EP22382119.0).
- Participation of Dr. Arnalich as coordinator and member of the database development committee in the international multicentre study 'Fight corneal blindness' in keratoconus with publication: Ferdi AC, Kandel H, Nguyen V, Tan J, Arnalich-Montiel F, Abbondanza M, Watson SL. Five-year corneal cross-linking outcomes: A Save Sight Keratoconus Registry Study. Clin Exp Ophthalmol. 2023 Jan;51(1):9-18. DOI: 10.1111/ceo.14177. PMID: 36240047.
Bibliometrics
ARTICLES | ACCUM. IF | MEAN IF | ARTICLES Q1 OR Q2 | % IN Q1 OR Q2 | ARTICLES D1 | % IN D1 | |
---|---|---|---|---|---|---|---|
2019 | 34 | 77.38 | 2.28 | 18 | 53 | 1 | 3 |
2020 | 42 | 80.85 | 2.04 | 13 | 31 | 1 | 2 |
2021 | 41 | 86.02 | 2.10 | 13 | 32 | 1 | 2 |
2022 | 25 | 66.38 | 2.66 | 9 | 36 | 0 | 0 |
2023 | 23 | 56.71 | 2.98 | 11 | 48 | 0 | 0 |
165 | 372.29 | 2.41 | 64 | 40 | 3 | 2 |
* Only original articles, editorial material, guidelines and reviews.